In line with the dsm-firmenich Group’s Ingredients strategy which includes DRT, we would like to communicate on our major investments in specialty resins to significantly increase our global supply capabilities and support our customers and markets.
At the Vielle-Saint-Girons site in France, DRT continue to build a brand-new state-of-the-art plant to produce hydrogenated rosin and resin derivatives. The company is pleased to announce today that this large-scale facility is expected to be completed in mid-2024. This investment will uniquely position the Group as a global supplier of hydrogenated rosin and resin derivatives with the highest degree of hydrogenation available on the market.
Additionally, we are planning to invest in debottlenecking our production line of polyterpene resins in France, which will be important to continuously support the growth of the markets using these resins.
At the same time, the Group is looking at implementing alliances to offer additional alternatives in rosin and terpene resins and meet the demand of a wide variety of specialized markets. These new partnerships will be announced as soon as possible. On a long-term basis, a dedicated team is working to study potential future investments in these specialty resins. Location and timing are being carefully assessed.
Our commitment to serve the current and future demand for specialty resins remains strong and determined. As a worldwide leader of biobased and sustainable ingredients, we will continue to invest to support the growth of our customers and markets.
Brand-new state-of-the-art plant under construction in France, which will produce hydrogenated rosin and resin derivatives.